- Trial phase
- Phase 2/3 (pivotal) for Becker muscular dystrophy; Phase 2 for Duchenne muscular dystrophy
- Time to market
- Potential FDA approval target end-2027 for Becker muscular dystrophy (if GRAND CANYON positive, NDA submission H1 2027). Duchenne program is earlier-stage (Phase 2).
- Why 4/10
- The next hard, dated catalyst is the GRAND CANYON pivotal topline readout in Q4 2026 (~3-5 months away). However, the drug was sold to Servier in a deal that closed July 13, 2026, with $1.55B upfront already banked by Edgewise. The readout determines up to $1.1B in milestone payments but is not existential for EWTX, which is now pivoting to a cardiovascular pipeline. ImpactScore 4: meaningful milestone catalyst but no longer the company's defining binary.
Sevasemten is no longer Edgewise's asset, it was sold to Servier. For EWTX holders, watch the GRAND CANYON readout (Q4 2026) which triggers up to $1.1B in milestone payments, but the stock's primary thesis now rests on the cardiovascular pipeline (EDG-7500). For non-EWTX investors, sevasemten's fate is in Servier's hands; there's no pure-play public stock directly tied to this drug.
Price Chart
Executive Summary
Sevasemten (EDG-5506) is an oral, first-in-class fast skeletal myosin inhibitor being developed for Becker and Duchenne muscular dystrophies, rare, progressive muscle-wasting diseases with no approved treatments for Becker. The Phase 2 CANYON trial met its primary endpoint, showing a 28% reduction in key muscle damage biomarkers and functional stabilization. On June 1, 2026, Edgewise sold sevasemten and its entire muscular dystrophy business to French pharma Servier for $1.55B upfront plus up to $1.1B in milestones (deal closed July 13, 2026). The pivotal GRAND CANYON study (175 patients, >98% powered) is fully enrolled with top-line results due Q4 2026. If positive, an NDA is planned for H1 2027 with potential approval by end-2027. For Edgewise (EWTX) investors, the $1.55B cash is already locked in; the stock now trades as a cardiovascular-focused company.
How It Works
Sevasemten is a pill that slows muscle damage in people with muscular dystrophy. It works by inhibiting a protein (fast skeletal myosin) that controls forceful muscle contractions, the kind that cause the most damage in fragile, dystrophic muscle. By dampening this contraction-driven injury, the drug aims to preserve muscle function and slow disease progression.
Trial Status
The GRAND CANYON pivotal cohort (Becker) is fully enrolled with 175 participants and >98% powered. Top-line results expected Q4 2026. U.S. NDA planned H1 2027 if positive. The Phase 2 CANYON study previously met its primary endpoint (28% reduction in TNNI2 muscle damage biomarker). Phase 2 Duchenne trials (LYNX, FOX) are ongoing with Phase 3 planning underway. The FDA declined accelerated approval based on Phase 2 data alone, requiring the pivotal GRAND CANYON data.
The Two-Sided Case
Upcoming Catalysts
- GRAND CANYON pivotal topline results, Q4 2026 (Becker muscular dystrophy)
- If positive, NDA submission to FDA, H1 2027
- Potential FDA approval, target end-2027
- Phase 2 Duchenne data updates (LYNX, FOX studies)
- Servier-initiated Phase 3 Duchenne study, recruitment start 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report